## **Payment Integrity Scorecard**

Program or Activity Centers for Medicare & Medicaid Services (CMS) Me.

Reporting Period Q4 2022

## **Change from Previous FY (\$M)**

\$528M




## HHS

Centers for Medicare & Medicaid Services (CMS)
Medicare Prescription Drug Benefit (Part D)

Brief Program Description:

Medicare Prescription Drug Benefit (Medicare Part D) is a federal prescription drug benefit program for Medicare beneficiaries.

Key	Milestones	Status	ECD	
1	Develop mitigation strategies to get the payment right the first time	Completed	Nov-19	
2	Evaluate the ROI of the mitigation strategy	Completed	Nov-19	
3	Determine which strategies have the best ROI to prevent cash loss	Completed	Nov-19	
4	Implement new mitigation strategies to prevent cash loss	Completed	Dec-20	
5	Analyze results of implementing new strategies	On-Track	Dec-22	
6	Achieved compliance with PIIA	Completed	Dec-21	
7	7 Identified any data needs for mitigation		Dec-22	



Goa	ls towards	Reducing Monetary Loss	Status	ECD		Recovery Method	Brief Description of PI Overpayme	
1	Q4 2022	Outreach to Plan Sponsors	On-Track	Dec-22	1	4	Recovery	HHS will be conducting da
2	Q4 2022	Training	On-Track	Dec-22		Activity	to recover inappropriate pa	

	Recovery	Brief Description of Plans to Recover	Brief Description of Actions Taken to
	Method	Overpayments	Recover Overpayments
1	Recovery Activity	HHS will be conducting data analysis and audits to recover inappropriate payments.	HHS conducts audits of Part D plan sponsors, with a focus on drugs at high risk of improper payments. Audits aim to educate Part D plan sponsors on issues of fraud, waste, and abuse, as well as to identify, reduce, and recover improper payments.

Accomplishments in Reducing Monetary Loss				
1	HHS conducted a Fraud, Waste, and Abuse Webinar in September 2022.	Sep-22		
2	HHS conducted an audit on Xyrem, a prescription medicine used to treat narcolepsy, and identified improper claims. HHS required plan sponsors to delete those prescription drug event records, thereby preventing improper payments from being made.	Oct-22		

Amt(\$)	Root Cause of Monetary Loss	Root Cause Description	Mitigation Strategy	Brief Description of Mitigation Strategy and Anticipated Impact
\$686M	Overpayments outside the agency control that occurred because of a Failure to Access Data/Information Needed.	The primary causes of Medicare Prescription Drug Plan (Part D) improper payments are drugs ineligible for coverage under Medicare Part D and insufficient documentation.		Reduce administrative or process errors made by other party through outreach efforts, improved policy based on statutory requirements, and expanded education to Part D sponsors.